Vitamin B12 and Parkinson's Disease: What is the Relationship?

Cardoso, Francisco

doi:10.1002/mds.27366

Cited by 6 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings were partially contradicted to their findings in serum, which show that low serum VitB12 at baseline predicted greater worsening of mobility, whereas elevated tHcy predicted greater cognitive decline (19). These ambiguous results were challenged by Cardoso (32). First, the metabolism of VitB12 could be induced by L-dopa (12,13).…”

Section: Discussionmentioning

confidence: 93%

See 1 more Smart Citation

Serum Folate, Vitamin B12 Levels, and Systemic Immune-Inflammation Index Correlate With Motor Performance in Parkinson's Disease: A Cross-Sectional Study

Zhang

Gao

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

This study aimed to investigate the influence of serum folate, vitamin B12 (VitB12) levels, and inflammation-based scores on the motor performance status in Parkinson's disease (PD). We retrospectively collected data from 148 consecutive patients with idiopathic PD first admitted to our hospital. We measured whole blood count, albumin, lactate dehydrogenase, C-reactive protein, folate, and VitB12 levels and calculated the inflammation-based scores. The following scales were applied to assess the motor performance status: activity of daily living scale (ADL, the Barthel Index), the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III), and Hoehn–Yahr (H–Y) classification. The geometric mean of folate and VitB12 levels were 11.87 (ng/ml) and 330.52 (pmol/L), respectively. Folate deficiency (serum level < 4.0 ng/ml) and VitB12 deficiency (serum level < 133 pg/ml) were present in 0.7 and 5.4% of the patients, respectively. The mean prognostic nutritional index (PNI) and systemic immune-inflammation index (SII) were 47.78 ± 4.42 and 470.81 ± 254.05, respectively. The multivariate analyses showed that serum VitB12 level (P = 0.002) and SII (P = 0.005) were significant factors for ADL score; serum folate (P = 0.027) and VitB12 (P = 0.037) levels for UPDRS-III score; and serum folate (P = 0.066) and VitB12 (P = 0.017) levels for H–Y classification. The elevated folate level did correlate with greater decline in UPDRS-III score (P = 0.023) and H–Y classification (P = 0.003), whereas there was an obvious increase in ADL score (P = 0.048). SII was negatively associated (P < 0.001) with the ADL score. The three-dimensional drawing, combined with the effect of folate and VitB12 levels, showed that the lowest level of folate was associated with the lowest ADL score and the highest UPDRS-III score and H–Y classification. This study indicates that serum folate, VitB12 levels, and SII are significant factors influencing the motor performance status in patients with PD. SII is negatively associated with ADL. Elevated serum folate level correlates with mild motor impairment in patients with PD.

show abstract

Section: Discussionmentioning

confidence: 93%

“…Genuine deficiency is only observed in few cases with extremely low levels. Finally, the measurement of VitB12 level should be adjusted for important confounding factors, especially the tHcy level (31,32).…”

Section: Discussionmentioning

confidence: 99%

Serum Folate, Vitamin B12 Levels, and Systemic Immune-Inflammation Index Correlate With Motor Performance in Parkinson's Disease: A Cross-Sectional Study

Zhang

Gao

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…Research studies showed that PD patients lacked V12 but had higher HCY (homocysteine), so V12 could improve cognitive disorder and other symptoms of PD [ 29 ]. Clinical tests on vitamin B12 for treating cognitive disorder and other nonmotor symptoms of PD have been terminated [ 30 ]. In this research, hydroxocobalamin (namely vitamin B12) had mutual effect with MTR and affected transmethylation of methyl cobalamin to HCY (homocysteine) and consequently it gave play to neuroprotection.…”

Section: Discussionmentioning

confidence: 99%

Potential Therapeutic Drugs for Parkinson’s Disease Based on Data Mining and Bioinformatics Analysis

Chen

et al. 2018

Parkinson's Disease

View full text Add to dashboard Cite

The objective is to search potential therapeutic drugs for Parkinson's disease based on data mining and bioinformatics analysis and providing new ideas for research studies on “new application of conventional drugs.” Method differential gene candidates were obtained based on data mining of genes of PD brain tissue, original gene data analysis, differential gene crossover, pathway enrichment analysis, and protein interaction, and potential therapeutic drugs for Parkinson's disease were obtained through drug-gene relationship. Result. 250 common differential genes were obtained from 3 research studies, and 31 differential gene candidates were obtained through gene enrichment analysis and protein interaction. 10 drugs such as metformin hydrochloride were directly or indirectly correlated to differential gene candidates. Conclusion. Potential therapeutic drugs that may be used for prevention and treatment of Parkinson's disease were discovered through data mining and bioinformatics analysis, which provided new ideas for research and development of drugs. Results showed that metformin hydrochloride and other drugs had certain therapeutical effect on Parkinson's disease, and melbine (DMBG) can be used for treatment of Parkinson's disease and type 2 diabetes patients.

show abstract

“…3 An important point to consider is that vitamin B12 deficiency can cause subacute combined deficiency, cognitive impairment due to white-matter disease, and peripheral neuropathy, which could certainly contribute to cognitive and gait impairment in PD; however, is by no means conclusive in patients with PD, and more evidence is needed. 37 Finally, although vitamin B12 appears to be related to acetylcholine through multiple mechanisms detailed above, given the multiple physiologic processes the transmethylation cycle is involved in throughout the CNS, vitamin B12 deficiency causing cholinergic dysfunction is unlikely to be a straightforward linear causal process. However, given the possible association between the two, as well as low-risk supplementation with vitamin B12, this relationship deserves further exploration.…”

Section: Vitamin B12 and Pd: A Potential Therapeutic Role?mentioning

confidence: 99%